These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 16040390)

  • 1. Selective depletion strategies in allogeneic stem cell transplantation.
    Mielke S; Solomon SR; Barrett AJ
    Cytotherapy; 2005; 7(2):109-15. PubMed ID: 16040390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving immune reconstitution while preventing GvHD in allogeneic stem cell transplantation.
    André-Schmutz I; Dal Cortivo L; Fischer A; Cavazzana-Calvo M
    Cytotherapy; 2005; 7(2):102-8. PubMed ID: 16040389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical-scale selective depletion of alloreactive T cells using an anti-CD25 immunotoxin.
    Michálek J; Collins RH; Vitetta ES
    Neoplasma; 2003; 50(4):296-9. PubMed ID: 12937844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective removal of alloreactive cells from haematopoietic stem cell grafts: graft engineering for GVHD prophylaxis.
    Koh MB; Prentice HG; Lowdell MW
    Bone Marrow Transplant; 1999 May; 23(10):1071-9. PubMed ID: 10373075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective depletion of alloreactive T lymphocytes using patient-derived nonhematopoietic stimulator cells in allograft engineering.
    Nonn M; Herr W; Khan S; Todorova M; Link I; Thies J; Distler E; Kaltwasser M; Hoffmann J; Huber C; Hartwig UF
    Transplantation; 2008 Nov; 86(10):1427-35. PubMed ID: 19034014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elimination of alloreactive T cells using photodynamic therapy.
    Boumédine RS; Roy DC
    Cytotherapy; 2005; 7(2):134-43. PubMed ID: 16040392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of GvHD by suicide-gene transduced donor T lymphocytes: clinical applications in mismatched transplantation.
    Ciceri F; Bonini C; Gallo-Stampino C; Bordignon C
    Cytotherapy; 2005; 7(2):144-9. PubMed ID: 16040393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimized clinical-scale culture conditions for ex vivo selective depletion of host-reactive donor lymphocytes: a strategy for GvHD prophylaxis in allogeneic PBSC transplantation.
    Solomon SR; Tran T; Carter CS; Donnelly S; Hensel N; Schindler J; Bahceci E; Ghetie V; Michálek J; Mavroudis D; Read EJ; Vitetta ES; Barrett AJ
    Cytotherapy; 2002; 4(5):395-406. PubMed ID: 12473206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective elimination of alloreactivity from immunotherapeutic T cells by photodynamic cell purging and memory T-cell sorting.
    Le NT; Chen BJ; Chao NJ
    Cytotherapy; 2005; 7(2):126-33. PubMed ID: 16040391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro methotrexate as a practical approach to selective allodepletion.
    Sathe A; Ortega SB; Mundy DI; Collins RH; Karandikar NJ
    Biol Blood Marrow Transplant; 2007 Jun; 13(6):644-54. PubMed ID: 17531774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiviral immunity and T-regulatory cell function are retained after selective alloreactive T-cell depletion in both the HLA-identical and HLA-mismatched settings.
    Davies JK; Koh MB; Lowdell MW
    Biol Blood Marrow Transplant; 2004 Apr; 10(4):259-68. PubMed ID: 15077224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving the ex vivo retroviral-mediated suicide-gene transfer process in T lymphocytes to preserve immune function.
    Robinet E; Fehse B; Ebeling S; Sauce D; Ferrand C; Tiberghien P
    Cytotherapy; 2005; 7(2):150-7. PubMed ID: 16040394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective T-cell depletion for haplotype-mismatched allogeneic stem cell transplantation.
    Bastien JP; Roy J; Roy DC
    Semin Oncol; 2012 Dec; 39(6):674-82. PubMed ID: 23206844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The history and future prospective of haplo-identical stem cell transplantation.
    Handgretinger R; Lang P
    Cytotherapy; 2008; 10(5):443-51. PubMed ID: 18615344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving outcome of allogeneic stem cell transplantation by immunomodulation of the early post-transplant environment.
    Barrett J
    Curr Opin Immunol; 2006 Oct; 18(5):592-8. PubMed ID: 16872820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytolytic pathways in haematopoietic stem-cell transplantation.
    van den Brink MR; Burakoff SJ
    Nat Rev Immunol; 2002 Apr; 2(4):273-81. PubMed ID: 12001998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progress and prospects: graft-versus-host disease.
    Mastaglio S; Stanghellini MT; Bordignon C; Bondanza A; Ciceri F; Bonini C
    Gene Ther; 2010 Nov; 17(11):1309-17. PubMed ID: 20508597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of high-stringency CD8 depletion of donor leukocyte infusions after allogeneic hematopoietic stem cell transplantation.
    Orti G; Lowdell M; Fielding A; Samuel E; Pang K; Kottaridis P; Morris E; Thomson K; Peggs K; Mackinnon S; Chakraverty R
    Transplantation; 2009 Dec; 88(11):1312-8. PubMed ID: 19996931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Selective depletion of alloreactive T cells and study of anti-tumor activity of specific T cell clones in patients with leukemia].
    Matejková E; Ocadlíková D; Smejkalová J; Muzíkova J; Raida L; Tousovská K; Pacasová R; Nenicková M; Tesarová E; Sterba J; Indrák K; Michálek J
    Klin Onkol; 2008; 21(3):104-9. PubMed ID: 19097419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.